154 related articles for article (PubMed ID: 28524162)
1. Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia.
Chakrabarty S; Varghese VK; Sahu P; Jayaram P; Shivakumar BM; Pai CG; Satyamoorthy K
Br J Cancer; 2017 Jun; 117(1):136-143. PubMed ID: 28524162
[TBL] [Abstract][Full Text] [Related]
2. Cancer-Associated Mutations in Endometriosis without Cancer.
Anglesio MS; Papadopoulos N; Ayhan A; Nazeran TM; Noë M; Horlings HM; Lum A; Jones S; Senz J; Seckin T; Ho J; Wu RC; Lac V; Ogawa H; Tessier-Cloutier B; Alhassan R; Wang A; Wang Y; Cohen JD; Wong F; Hasanovic A; Orr N; Zhang M; Popoli M; McMahon W; Wood LD; Mattox A; Allaire C; Segars J; Williams C; Tomasetti C; Boyd N; Kinzler KW; Gilks CB; Diaz L; Wang TL; Vogelstein B; Yong PJ; Huntsman DG; Shih IM
N Engl J Med; 2017 May; 376(19):1835-1848. PubMed ID: 28489996
[TBL] [Abstract][Full Text] [Related]
3. Polarity gene alterations in pure invasive micropapillary carcinomas of the breast.
Gruel N; Benhamo V; Bhalshankar J; Popova T; Fréneaux P; Arnould L; Mariani O; Stern MH; Raynal V; Sastre-Garau X; Rouzier R; Delattre O; Vincent-Salomon A
Breast Cancer Res; 2014 May; 16(3):R46. PubMed ID: 24887297
[TBL] [Abstract][Full Text] [Related]
4. Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status.
Shaykevich A; Chae D; Silverman I; Bassali J; Louloueian N; Siegman A; Bandyopadhyaya G; Goel S; Maitra R
Invest New Drugs; 2024 Apr; 42(2):229-239. PubMed ID: 38446332
[TBL] [Abstract][Full Text] [Related]
5. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.
Liu H; Murphy CJ; Karreth FA; Emdal KB; White FM; Elemento O; Toker A; Wulf GM; Cantley LC
Cancer Discov; 2018 Mar; 8(3):354-369. PubMed ID: 29203461
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling of visible polypoid and invisible conventional intestinal-type low-grade dysplasia in patients with idiopathic inflammatory bowel disease.
Christakis A; Nowak J; Hamilton MJ; Goldblum JR; Parrack P; Lindeman NI; Odze R; Patil DT
J Clin Pathol; 2024 Jun; ():. PubMed ID: 38886044
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer.
Li X
BMC Cancer; 2017 Apr; 17(1):252. PubMed ID: 28390392
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiles of Indonesian colorectal cancer patients.
Abdullah M; Meilany S; Trimarsanto H; Malik SG; Sukartini N; Idrus F; Nursyirwan SA; Muzellina VN; Pribadi RR; Utari AP; Maulahela H; Syam AF
F1000Res; 2022; 11():443. PubMed ID: 37125020
[No Abstract] [Full Text] [Related]
9. Ustekinumab: A Review in Moderate to Severe Crohn's Disease.
Lamb YN; Duggan ST
Drugs; 2017 Jul; 77(10):1105-1114. PubMed ID: 28528528
[TBL] [Abstract][Full Text] [Related]
10. Rectal-sparing type of ulcerative colitis predicts lack of response to pharmacotherapies.
Horio Y; Uchino M; Bando T; Chohno T; Sasaki H; Hirata A; Takesue Y; Ikeuchi H
BMC Surg; 2017 May; 17(1):59. PubMed ID: 28526076
[TBL] [Abstract][Full Text] [Related]
11. Dietary Therapy With the Crohn's Disease Exclusion Diet is a Successful Strategy for Induction of Remission in Children and Adults Failing Biological Therapy.
Sigall Boneh R; Sarbagili Shabat C; Yanai H; Chermesh I; Ben Avraham S; Boaz M; Levine A
J Crohns Colitis; 2017 Oct; 11(10):1205-1212. PubMed ID: 28525622
[TBL] [Abstract][Full Text] [Related]
12. Histologic scoring indices for evaluation of disease activity in ulcerative colitis.
Mosli MH; Parker CE; Nelson SA; Baker KA; MacDonald JK; Zou GY; Feagan BG; Khanna R; Levesque BG; Jairath V
Cochrane Database Syst Rev; 2017 May; 5(5):CD011256. PubMed ID: 28542712
[TBL] [Abstract][Full Text] [Related]
13. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
[TBL] [Abstract][Full Text] [Related]
14. Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial.
Cox SR; Prince AC; Myers CE; Irving PM; Lindsay JO; Lomer MC; Whelan K
J Crohns Colitis; 2017 Dec; 11(12):1420-1429. PubMed ID: 28525543
[TBL] [Abstract][Full Text] [Related]
15. Classification of Paediatric Inflammatory Bowel Disease using Machine Learning.
Mossotto E; Ashton JJ; Coelho T; Beattie RM; MacArthur BD; Ennis S
Sci Rep; 2017 May; 7(1):2427. PubMed ID: 28546534
[TBL] [Abstract][Full Text] [Related]
16. Adherence to an elemental diet for preventing postoperative recurrence of Crohn's disease.
Ohara N; Mizushima T; Iijima H; Takahashi H; Hiyama S; Haraguchi N; Inoue T; Nishimura J; Shinzaki S; Hata T; Matsuda C; Yamamoto H; Doki Y; Mori M
Surg Today; 2017 Dec; 47(12):1519-1525. PubMed ID: 28534264
[TBL] [Abstract][Full Text] [Related]
17. Association of ulcerative colitis with transcobalamin II gene polymorphisms and serum homocysteine, vitamin B
Zheng S; Yang W; Wu C; Sun L; Lin D; Lin X; Jiang L; Ding R; Jiang Y
Immunogenetics; 2017 Jul; 69(7):421-428. PubMed ID: 28526947
[TBL] [Abstract][Full Text] [Related]
18. Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease.
Sieczkowska-Golub J; Meglicka M; Plocek A; Banaszkiewicz A; Jarzębicka D; Toporowska-Kowalska E; Gawronska A; Oracz G; Kierkus J
J Pediatr Gastroenterol Nutr; 2017 Sep; 65(3):285-288. PubMed ID: 28542043
[TBL] [Abstract][Full Text] [Related]
19. Dose escalation of biologics in Crohn's disease: critical review of observational studies.
Einarson TR; Bereza BG; Ying Lee X; Lelli F
Curr Med Res Opin; 2017 Aug; 33(8):1433-1449. PubMed ID: 28537467
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Archer R; Stevens JW; Goka E; Clowes M; Scott DL; Young A
Pharmacoeconomics; 2017 Nov; 35(11):1141-1151. PubMed ID: 28550592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
